The ADCS and the Mission of this Initiative
The Alzheimer’s Disease Cooperative Study (ADCS) at the University of California, San Diego (UCSD) is currently seeking research proposals for combination therapy initiatives that address a spectrum of disease targets and mechanisms in Alzheimer’s Disease (AD). Combining multiple drugs or designing treatments that include a combination of pharmacological and lifestyle interventions that target multiple pathways could be an effective therapeutic approach, and aligns with the NIH Research Implementation Milestones as well as Alzheimer’s Association (AA) priorities.
This initiative focuses on cutting-edge projects primed for clinical trial. The intent of this program is to establish a collaboration with the ADCS to accelerate successful, external peer-reviewed grant applications to fund proof of concept multi-site combination therapy trials. Of particular interest are proposals that have promising single-site pilot or phase I data available to support the application.
Major Strategic Priorities
Major strategic priorities include but are not limited to multi-modal interventions that include a combination of any of the following:
- Non-pharmacological lifestyle interventions (i.e. sleep, social engagement, exercise, cognitive training)
- Repurposed compounds
- Natural products
- Novel candidates
- Existing treatments for AD in combination with any of the above
Projects that include only a single drug or non-pharmacological candidate are welcome with the understanding that we will work to identify other promising candidates to evaluate in combination.
Please download the complete RFP for more details
Deadlines and Contact Information
This initial call for LOIs will close on August 15, 2023 acceptable on a rolling basis thereafter.
Selected ideas will be invited to submit a more detailed proposal for presentation to an Intervention Selection Committee before beginning the development of a grant proposal to the appropriate agency.